Friday June 23, 2017

Articles:225


5

August 08

Anti-IgE Therapy Advances Care for Asthma in patients 50 years or older

Anti-IgE (Omalizumab) is approved for the treatment of severe allergic asthma. In a recent study published in Annals of Allergy, Asthma and immunology, compared with the pretrial period omalizumab treatment reduced the rate of severe exacerbations in patients 50 years or older by 68.9% (P < .001) and in patients younger than 50 years by 75.4% (P < .001). After 4 months there was a marked reduction of daily asthma symptoms and nocturnal awakenings by 67.8% and 72.6% in the older and by 79.3% and 82.5% in the younger patients, respectively (P < .001, all 4 comparisons). In 60% of patients 50 years or older lung function improved compared with 69% of patients younger than 50 years. Efficacy of omalizumab was rated as excellent or good by most physicians in patients 50 years or older (68.4%) and younger than 50 years (76.8%, P = .05 elderly vs younger). Adverse events were reported in 35.5% of patients 50 years or older and 32.1% of patients younger than 50 years. (Ann Allergy Asthma Immunol. 2010 Oct;105(4):313-9.)


August 07

Advances in Urticaria Treatment with Dapsone

Pressure urticaria as a subform of physical urticaria is rare and treatment is often difficult. Established therapeutic regimes include antihistamines (generally exceeding approved dosages in order to achieve a therapeutic benefit) or antihistamines combined with montelukast. Complete relief of symptoms is difficult. Dapsone has been ben used as an early therapeutic alternative in the event of treatment failure and established a standardized therapeutic regime in our office. As recently reported (J Dtsch Dermatol Ges. 2011 Jul 20. doi: 10.1111/j.1610-0387.2011.07749.x. [Epub ahead of print]),  approximately 74 % of patients in whom symptoms persisted despite established therapies, the results of treatment with dapsone were good or very good. No significant effects were found related to age, gender, duration of therapy, side-effects, or Met-Hb elevation (a tendency toward a decreased benefit was associated with middle-age, male sex, shorter duration of therapy, observed side-effects, and Met-Hb elevation). Thus is appeasr that dapsone is well tolerated and results in a good therapeutic benefit which lasts after termination of therapy. With adequate monitoring, the use of dapsone in patients with pressure urticaria has such a good risk-benefit ratio that individuals should consider early treatment initiation.

© The Authors • Journal compilation © Blackwell Verlag GmbH, Berlin.

 

August 06

CAM or SCAM

CAM (complementary and Alternative Medicine) - some physicians call it SCAM (Supplements, Complementary and Alternative Medicine)

 

A poll of physicians showed that 31% of respondents supported their patients' use of alternate paths of treatment. Only 18% discouraged it as a general rule, and a full 38% advocated "telling [patients] there is little evidence one way or the other and leaving it open."


August 06

Transcription Factor

A transcription factor that is usually only expressed in fetal stem cells can make adult blood stem cells act like their younger counterparts. The findings hold promise for treating leukemia by converting cancerous adult stem cells, which are driven by pro-cancer growth signals, into fetal stem cells, which don’t respond to those signals. (study published in August 2011 in Genes and Development).


August 05

Mold Allergy and Pediatric Asthma

When infants are exposed to mold in the home, their risk for developing asthma more than doubles, according to a study published Tuesday in the Annals of Allergy, Asthma & Immunology. The study doesn't prove mold causes asthma, but it does suggest that exposure to mold during infancy is linked to the development of chronic inflammation of the lung airways, which causes wheezing, shortness of breath, chest tightness, and coughing.

http://bit.ly/p4bjFx


<- | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45->
Location: Springfield, NJ
Today's Date: June 23, 2017
Station Director: Leonard Bielory, M.D
Site Administrator: info@nynjpollen.com